What’s the current market cap for Alpha Tau Medical Ltd. stock?

Alpha Tau Medical Ltd. (DRTS) has a market cap of $981m as of June 28, 2026.

What is the P/E ratio for Alpha Tau Medical Ltd. stock?

The price to earnings (P/E) ratio for Alpha Tau Medical Ltd. (DRTS) stock is 0 as of June 28, 2026.

Does Alpha Tau Medical Ltd. stock pay dividends?

No, Alpha Tau Medical Ltd. (DRTS) stock does not pay dividends to its shareholders as of June 28, 2026.

When is the next Alpha Tau Medical Ltd. dividend payment date?

Alpha Tau Medical Ltd. (DRTS) stock does not pay dividends to its shareholders.

What is the beta indicator for Alpha Tau Medical Ltd.?

Alpha Tau Medical Ltd. (DRTS) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Alpha Tau Medical Ltd. stock | $DRTS Share Price

13:30

15:10

16:45

18:25

20:00

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Ticker

$DRTS

Sector

Health

Primary listing

NASDAQ

Employees

121

Headquarters

Jerusalem, Israel

Website

www.alphatau.com

DRTS Metrics

BasicAdvanced

$981m

-$0.67

1.12

Bulls say / Bears say

Japan’s Ministry of Health, Labour and Welfare granted Shonin (marketing) approval for the Alpha DaRT® system in unresectable locally advanced or recurrent head and neck cancer on February 24, 2026, marking the first regulatory clearance outside Israel (Reuters)

Enrollment in the ReSTART pivotal U.S. multicenter trial for recurrent cutaneous squamous cell carcinoma was completed with 88 patients, advancing the rolling PMA submission toward potential FDA approval (Reuters)

Interim data from the U.S. REGAIN glioblastoma trial showed 100 percent local disease control and a 67 percent complete response rate in the first three patients, highlighting strong potential in a high-unmet-need indication (Nasdaq)

First-quarter 2026 EPS of $-0.26 missed the consensus of $-0.12 and reported revenue was only $5,000 versus $47,250 expected, underscoring negligible commercial receipts (Reuters)

Operating loss widened to $13.3 million in Q1 2026 from $9.3 million a year earlier, highlighting accelerated cash burn and potential need for additional financing (Nasdaq)

Shares slipped 8 percent over the week to May 8, 2026, reflecting high stock volatility and sensitivity to trial and financing updates (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

First-quarter 2026 EPS of $-0.26 missed the consensus of $-0.12 and reported revenue was only $5,000 versus $47,250 expected, underscoring negligible commercial receipts (Reuters)

Operating loss widened to $13.3 million in Q1 2026 from $9.3 million a year earlier, highlighting accelerated cash burn and potential need for additional financing (Nasdaq)

Shares slipped 8 percent over the week to May 8, 2026, reflecting high stock volatility and sensitivity to trial and financing updates (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.